Stock Appreciation Rights (Details) (Stock Appreciation Rights (SARs) [Member], USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
SARS Valuation Assumptions [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	360,000	320,000	360,000	320,000
Stock Appreciation Rights, Weighted Average Grant Price	$ 0.409	$ 0.417	$ 0.409	$ 0.417
Stock Appreciation Rights, Weighted Average Contractual Life Remaining	4.91	5.36	4.91	5.36
Stock Appreciation Rights, Weighted Average Market Price			$ 1.200	$ 0.281
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate			137.52%	150.38%
Weighted Average Expected Life	4.42	4.72	4.42	4.72
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.10%	0.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%
Stock Appreciation Rights, Weighted Average Fair Value Price			$ 1.143	$ 0.260
Weighted Average Aggregate Fair Value			$ 290,000	$ 56,000
Weighted Average Aggregate Intrinsic Value			220,000	2,000
Stock Appreciation Rights, Compensation Expense	124,000	2,000	217,000	8,800
Unrecognized Compensation Expense Related to Non-Vested SARS Granted			68,000	15,000
Expected Period to Recognize Compensation Expense Related to Non-Vested SARSs Granted	1.94	2.08	1.94	2.08
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	$ 313,000	$ 61,000	$ 313,000	$ 61,000
Maximum [Member]
SARS Valuation Assumptions [Line Items]
Stock Appreciation Rights, Upper Range of Grant Price	$ 0.695	$ 0.695	$ 0.695	$ 0.695
Minimum [Member]
SARS Valuation Assumptions [Line Items]
Stock Appreciation Rights, Lower Range of Grant Price	$ 0.208	$ 0.208	$ 0.208	$ 0.208